V

Vifor Pharma AG
SIX:VIFN

Watchlist Manager
Vifor Pharma AG
SIX:VIFN
Watchlist
Price: 166.15 CHF 0.48%
Market Cap: CHf10.8B

Operating Margin

20.1%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
20.1%
=
Operating Income
CHf351.8m
/
Revenue
CHf1.8B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
20.1%
=
Operating Income
CHf351.8m
/
Revenue
CHf1.8B

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Vifor Pharma AG
SIX:VIFN
10.8B CHF
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
270B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
218.4B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.9B EUR
Loading...

Market Distribution

Higher than 77% of companies in Switzerland
Percentile
77th
Based on 1 083 companies
77th percentile
20.1%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Vifor Pharma AG
Glance View

Market Cap
10.8B CHF
Industry
Pharmaceuticals

Vifor Pharma AG, originally a small entity in the Swiss pharmaceutical landscape, has carved out a niche specializing in iron deficiency therapies and treatments. The company's journey began with an acute recognition of the global prevalence of iron deficiency and its profound impact on health. This focus allowed Vifor Pharma to fill a critical gap in the medical market, driving innovation within a specific therapeutic area that, until their entrance, was underserved. Beyond iron deficiency, they expanded into other selective therapeutic sectors such as nephrology, offering solutions for patients with chronic kidney disease. These strategic choices propelled Vifor to diversify its portfolio with specialized products that address significant unmet medical needs, fostered through both in-house R&D efforts and strategic partnerships with global biotech firms. The operational model of Vifor Pharma is intricately tied to its stronghold on niche pharmaceuticals, making money through a blend of proprietary product sales and strategic licensing or partnership agreements. Its flagship product, Ferinject, a novel intravenous iron replacement therapy, exemplifies Vifor’s capability to transform research into lucrative market solutions. Revenue is bolstered through partnerships with other pharmaceutical giants, which help distribute and co-market these solutions globally, thus expanding Vifor’s reach and market penetration. By focusing on specialized treatments and harnessing relationships that extend its distribution potential, Vifor Pharma has consistently honed its ability to balance innovation with strategic commercialization, underpinning its steady financial growth in the global pharmaceutical arena.

VIFN Intrinsic Value
Not Available
V
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
20.1%
=
Operating Income
CHf351.8m
/
Revenue
CHf1.8B
How has Operating Margin changed over time?

Over the last 3 years, Vifor Pharma AG’s Operating Margin has increased from 14.4% to 20.1%. During this period, it reached a low of 14.4% on Dec 1, 2018 and a high of 20.3% on Jun 30, 2021.

Back to Top